PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies

Trial Profile

PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Busulfan (Primary) ; Decitabine (Primary) ; Fludarabine (Primary)
  • Indications Acute myeloid leukaemia; Transplant rejection
  • Focus Therapeutic Use
  • Acronyms Decitabine Plus Mini Flu-Bu
  • Most Recent Events

    • 07 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
    • 26 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top